Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brain Benefits Boost Roche's Alecensa In ALK Lung Cancer Race

Executive Summary

Data from two studies confirm Alecensa's superiority over Pfizer's Xalkori and help Roche close the gap on Novartis' Zykadia.

Advertisement

Related Content

Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval
Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific
Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel